High-Conviction Short Positioning
SELLAS Life Sciences Group (SLS) is heading into its latest earnings print with one of the most aggressive short-interest profiles in the small-cap biotech sector. According to Ortex data, 39% of the company's free float is currently held short. This level of bearish conviction is compounded by a lending market that is effectively locked, leaving little room for new short positions without significant cost increases.
Market Dynamics
The stock has faced substantial downward pressure, falling 33% recently. With the lending market near its tightest, the setup is primed for volatility. Investors should monitor for any signs of a squeeze, as the high short interest relative to the float creates a precarious environment for those currently holding short positions if the earnings report triggers a positive price reaction.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.